Nine of 18 patients (50%) received treatment with corticosteroids, either due to lack of recovery of ALT (n = 4), recurrence of liver toxicity after restart of pazopanib (n = 2) or simultaneously with pazopanib restart (n = 3). The gene discussed is GPT; the disease is toxicity.